UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

Haematologica (Roma), 2021-04, Vol.106 (4), p.1047-1055

2021

Volltextzugriff (PDF)

Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7− CD4+ T‐cells

Cytometry. Part B, Clinical cytometry, 2021-03, Vol.100 (2), p.183-191

2021

Volltextzugriff (PDF)

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

American journal of hematology, 2015-11, Vol.90 (11), p.1091-1092

2015

Volltextzugriff (PDF)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing

Oncotarget, 2018-02, Vol.9 (9), p.8441-8449

2018

Volltextzugriff (PDF)

Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis

The American journal of surgical pathology, 2017-01, Vol.41 (1), p.82-93

2017

Volltextzugriff (PDF)

Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge

Clinical lymphoma, myeloma and leukemia, 2014-08, Vol.14 (4), p.e115-e118

2014

Volltextzugriff (PDF)

Adhesive capsulitis mimicking metastasis on 18F-FDG-PET/CT

Clinical nuclear medicine, 2015-02, Vol.40 (2), p.e145-e147

2015

Volltextzugriff (PDF)

A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone

International journal of dermatology, 2013-09, Vol.52 (9), p.1111-1114

2013

Volltextzugriff (PDF)

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

Modern pathology, 2009-01, Vol.22 (1), p.50-57

2009

Volltextzugriff (PDF)

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia: Methods and Best Applications

Clinical lymphoma, myeloma and leukemia, 2011-06, Vol.11, p.S49-S53

2011

Volltextzugriff (PDF)

Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient

Leukemia research, 2009-11, Vol.33 (11), p.e186-e188

2009

Volltextzugriff (PDF)

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.9385-9386

2022

Volltextzugriff (PDF)

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood, 2023-11, Vol.142 (Supplement 1), p.322-322

2023

Volltextzugriff (PDF)

Advancing Diagnostic Accuracy and Quality of Patient Care Through the Implementation of a Flow Cytometry Quality Assurance Program

Archives of pathology & laboratory medicine (1976), 2024-06

2024

Volltextzugriff (PDF)

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.2374-2374

2021

Volltextzugriff (PDF)

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Blood, 2021-11, Vol.138 (Supplement 1), p.793-793

2021

Volltextzugriff (PDF)

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood, 2022-11, Vol.140 (Supplement 1), p.11698-11701

2022

Volltextzugriff (PDF)

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.2267-2269

2022

Volltextzugriff (PDF)

1 – 25 von 187

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(164)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Englisch
(185)
Deutsch
(2)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(18)
Male
(11)
Female
(8)
Aged
(7)
Hematology, Oncology And Palliative Medicine
(7)
Middle Aged
(7)
Adult
(6)
Flow Cytometry
(6)
Immunohistochemistry
(5)
Immunophenotyping
(5)
Adolescent
(4)
Biological And Medical Sciences
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Social Sciences
(4)
Treatment Outcome
(4)
Aged, 80 And Over
(3)
Antibodies
(3)
Pathology
(3)
Biopsy
(2)
Bone Marrow - Pathology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm

Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26− or CD7− CD4+ T‐cells

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing

Distinguishing Between Hepatosplenic T-cell Lymphoma and γδ T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis

Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge

Adhesive capsulitis mimicking metastasis on 18F-FDG-PET/CT

A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia: Methods and Best Applications

Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Advancing Diagnostic Accuracy and Quality of Patient Care Through the Implementation of a Flow Cytometry Quality Assurance Program

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Aktive Filter

Suchergebnisse filtern